Institution
Sunovion
Company•London, United Kingdom•
About: Sunovion is a company organization based out in London, United Kingdom. It is known for research contribution in the topics: Lurasidone & Placebo. The organization has 572 authors who have published 1022 publications receiving 18488 citations. The organization is also known as: Sunovion Pharmaceuticals, Inc..
Topics: Lurasidone, Placebo, Population, Eszopiclone, Atypical antipsychotic
Papers published on a yearly basis
Papers
More filters
TL;DR: A final set of criteria that include updated considerations of subject age, clinical semiology, EEG and imaging results, use of prior and current therapies, co-occurring conditions, and suicidality, among others are agreed.
9 citations
TL;DR: Specific manic symptoms were found to be linked to sleep disturbance (characterized as a "bridge" symptom), which in turn linked the manic and depressive symptom clusters.
8 citations
Patent•
19 Aug 2002TL;DR: Methods of preparing, and compositions comprising, derivatives of (−)-venlafaxine are disclosed in this paper, where methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, Attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.
Abstract: Methods of preparing, and compositions comprising, derivatives of (−)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.
8 citations
TL;DR: In subjects with moderate to severe COPD, single-day administrations of ARF15 BID or ARF30 QD were associated with FEV(1) responses over a period of 24 hours that were considered equivalent per the protocol definition employed in the present study.
8 citations
8 citations
Authors
Showing all 572 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Chris H. Senanayake | 58 | 588 | 12142 |
| Paul J. Reider | 55 | 344 | 9827 |
| Antony Loebel | 42 | 223 | 6906 |
| Kenneth S. Koblan | 40 | 96 | 4380 |
| Richard G. Ball | 37 | 142 | 3684 |
| Robert D. Larsen | 36 | 147 | 3544 |
| Robert Goldman | 35 | 110 | 7064 |
| Raymond L. Woosley | 34 | 115 | 3811 |
| Rudy Schreiber | 33 | 80 | 3793 |
| Thomas R. Verhoeven | 29 | 127 | 3135 |
| Andrei Pikalov | 28 | 120 | 2583 |
| David Blum | 27 | 89 | 2958 |
| Mark A. Varney | 26 | 41 | 4032 |
| Lisa DiMichele | 25 | 88 | 1755 |
| John P. Hanrahan | 25 | 46 | 2781 |